全体要約
間質性肺疾患（ILD）市場は、2023年において数百万米ドルの価値があり、2030年までに同様の規模に調整されると予測されています。北米、アジア太平洋、ヨーロッパの各市場も同様に成長が見込まれています。主要企業には、ボーリンガーインゲルハイム、ベレロフォン・セラピューティクス、バイエル、フィリップス、メルク、シーメンス・ヘルスケアが含まれ、2023年には上位5社が市場の約%を占めています。
このレポートは、間質性肺疾患（ILD）の市場規模、主要企業の市場シェア、地域別および国別の分析を提供します。市場は、間質性肺炎、特発性肺線維症、非特異的間質性肺炎などのタイプに分かれ、成人と子供のアプリケーションに応じたセグメンテーションが行われています。
関連する質問
Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, Merck, Siemens Healthineers
肺胞周囲の炎症と瘢痕化, 治療法の進展, 市場競争の激化
概要
間質性肺疾患 (ILD) の世界市場は2023年にXX米ドルの価値があると推定され、2030年にはXX米ドルの規模に再調整されると予測されています。また、2024年から2030年の予測期間中の年平均成長率（CAGR）はXX%です。
2023年の北米間質性肺疾患（ILD）の市場価値は百万ドルであり、2030年には百万ドルに達する見込みであり、2024年から2030年の予測期間中にCAGRはXX%です。
アジア太平洋地域の間質性肺疾患（ILD）市場は2023年に$百万の価値があり、2030年には$百万に達し、2024年から2030年までの予測期間中にXX%のCAGRを記録する見込みです。
2023年の欧州市場における間質性肺疾患（ILD）の価値は数百万ドルで、2030年までに数百万ドルに達する見込みです。2024年から2030年までの予測期間中の年平均成長率（CAGR）はXX%です。
間質性肺疾患（ILD）の世界の主要企業には、ボーリンガーインゲルハイム、ベレロフォン・セラピューティクス社、バイエル、フジレバイオ（ミラカ）、フィリップス、メルク、シーメンスヘルスイニアーズなどが含まれます。2023年には、世界の5大企業が収益の約XX%を占めています。
報告の範囲
この報告書は、間質性肺疾患（ILD）の世界市場に関する包括的なプレゼンテーションを提供することを目的としています。全体的な売上収益、主要企業の市場シェアとランキング、および地域・国別、タイプ別、用途別の間質性肺疾患（ILD）の分析に焦点を当てています。
間質性肺疾患（ILD）市場の規模、推定、および予測は、2023年を基準年とし、2019年から2030年までの期間における販売収益（百万ドル）で提供されます。定量的および定性的な分析を通じて、読者がビジネスや成長戦略を開発し、市場競争の状況を評価し、現在の市場における自らの位置を分析し、間質性肺疾患（ILD）に関する情報に基づいたビジネス判断を行うのに役立てます。
市場セグメンテーション
会社別
ボーリング・インゲルハイム
ベルロフォーン・セラピューティクス株式会社
バイエル
フジレイビオ（ミラカ）
フィリップス
メルク
シーメンスヘルスケア
タイプ別セグメント:
間質性肺炎
特発性肺線維症
特発性間質性肺炎
過敏性肺炎
クリプトジェニック組織球肺炎
急性間質性肺炎
剥脱性間質性肺炎
その他
用途別セグメント
大人
子供
地域別
北米
アメリカ合衆国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東＆アフリカ
トルコ
サウジアラビア
UAE（アラブ首長国連邦）
章の概要
第1章：レポートの範囲、グローバルな総市場規模を紹介します。この章では、市場の動態、最新の市場動向、市場の推進要因や制約要因、業界の製造業者が直面する課題やリスク、業界に関連する政策の分析も提供します。
第2章：間質性肺疾患（ILD）メーカーの競争状況、収益市場シェア、最新の開発計画、合併および買収情報などの詳細分析です。
第3章: タイプ別の様々な市場セグメントの分析を提供し、市場シェアと各市場セグメントの発展可能性をカバーして、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助けます。
第4章：さまざまな市場セグメントの分析を提供し、アプリケーション別に各市場セグメントの市場規模と成長ポテンシャルをカバーして、読者が異なる下流市場でブルーオーシャン市場を見つける手助けをします。
第5章：地域レベルにおける間質性肺疾患（ILD）の収益。各地域の市場規模と発展可能性の定量的分析を提供し、世界各国の市場開発、将来的な発展の展望、市場のスペース、および市場規模を紹介します。
第6章: 国内の間質性肺疾患（ILD）の収益。国/地域ごとにタイプおよびアプリケーション別のシグマデータを提供します。
第7章：市場の主要企業の基本状況を詳細に紹介し、主要プレーヤーのプロフィールを提供します。これには、製品収益、粗利益、製品紹介、最近の開発などが含まれます。
第8章：産業チェーンの分析、業界の上流および下流を含む。
第9章: 結論。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 市場概要
1.1 間質性肺疾患（ILD） : プロダクトのイントロダクション
1.2 グローバルの市場規模、市場予測
1.3 間質性肺疾患（ILD）市場トレンドと成長ドライバー
1.3.1 間質性肺疾患（ILD）業界トレンド
1.3.2 間質性肺疾患（ILD）市場のドライバーと事業機会
1.3.3 間質性肺疾患（ILD）市場の課題
1.3.4 間質性肺疾患（ILD）市場の抑制要因
1.4 前提条件と限界
1.5 調査の目的
1.6 対象年
2 競合分析、企業別
2.1 グローバルの間質性肺疾患（ILD）、プレイヤー収益ランキング（2023年）
2.2 グローバルにおける間質性肺疾患（ILD）市場の収益規模、企業別（2019年～2024年）
2.3 間質性肺疾患（ILD）の主要企業、製造・販売拠点およびヘッドクオーター
2.4 間質性肺疾患（ILD）の主要企業、製品展開
2.5 間質性肺疾患（ILD）の主要企業、量産開始時期
2.6 間質性肺疾患（ILD）市場の競争状況分析
2.6.1 間質性肺疾患（ILD）市場集中度比率（2019年～2024年）
2.6.2 グローバルの間質性肺疾患（ILD）、上位企業5～10社の収益（2023年）
2.6.3 グローバルの間質性肺疾患（ILD）、Tier別上位企業（Tier 1、Tier 2、Tier 3）、2023年の収益ベース
2.7 M&A、拡大
3 セグメンテーション、タイプ別
3.1 イントロダクション、タイプ別
3.1.1 間質性肺炎
3.1.2 特発性肺線維症
3.1.3 非特異的間質性肺炎
3.1.4 過敏性肺炎
3.1.5 隠微性器質化肺炎
3.1.6 急性間質性肺炎
3.1.7 落屑性間質性肺炎
3.1.8 その他
3.2 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、タイプ別
3.2.1 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、タイプ別（2019年、2023年、2030年）
3.2.2 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、タイプ別（2019年～2030年）
3.2.3 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、タイプ別（%）（2019年～2030年）
4 セグメンテーション、用途別
4.1 イントロダクション、用途別
4.1.1 成人
4.1.2 子どもたち
4.2 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、用途別
4.2.1 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、用途別（2019年、2023年、2030年）
4.2.2 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、用途別（2019年～2030年）
4.2.3 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、用途別（%）（2019年～2030年）
5 セグメンテーション、地域別
5.1 グローバルの間質性肺疾患（ILD）の売上規模、金額ベース、地域別
5.2 北米
5.2.1 北米の間質性肺疾患（ILD）売上規模、金額ベース、2019年～2030年
5.2.2 北米の間質性肺疾患（ILD）の売上規模、金額ベース、国別（%）、2023年、2030年
5.3 ヨーロッパ
5.3.1 ヨーロッパの間質性肺疾患（ILD）売上規模、金額ベース、2019年～2030年
5.3.2 ヨーロッパの間質性肺疾患（ILD）の売上規模、金額ベース、国別（%）、2023年、2030年
5.4 アジア太平洋
5.4.1 アジア太平洋の間質性肺疾患（ILD）売上規模、金額ベース、2019年～2030年
5.4.2 アジア太平洋の間質性肺疾患（ILD）の売上規模、金額ベース、国別（%）、2023年、2030年
5.5 南米
5.5.1 南米の間質性肺疾患（ILD）売上規模、金額ベース、2019年～2030年
5.5.2 南米の間質性肺疾患（ILD）の売上規模、金額ベース、国別（%）、2023年、2030年
5.6 中東・アフリカ
5.6.1 中東・アフリカの間質性肺疾患（ILD）売上規模、金額ベース、2019年～2030年
5.6.2 中東・アフリカの間質性肺疾患（ILD）の売上規模、金額ベース、国別（%）、2023年、2030年
6 主要国・地域によるセグメンテーション
6.1 主要国・地域の間質性肺疾患（ILD）の売上成長トレンド、金額ベース（2019年、2023年、2030年）
6.2 主要国・地域の間質性肺疾患（ILD）の売上、金額ベース
6.3 米国
6.4 ヨーロッパ
6.5 中国
6.6 日本
6.7 韓国
6.8 東南アジア
6.9 インド
7 企業プロファイル
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim : プロファイル
7.1.2 Boehringer Ingelheim : 主な事業
7.1.3 Boehringer Ingelheim : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.1.4 Boehringer Ingelheim : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.1.5 Boehringer Ingelheim：近況
7.2 Bellerophon Therapeutics, Inc
7.2.1 Bellerophon Therapeutics, Inc : プロファイル
7.2.2 Bellerophon Therapeutics, Inc : 主な事業
7.2.3 Bellerophon Therapeutics, Inc : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.2.4 Bellerophon Therapeutics, Inc : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.2.5 Bellerophon Therapeutics, Inc：近況
7.3 Bayer
7.3.1 Bayer : プロファイル
7.3.2 Bayer : 主な事業
7.3.3 Bayer : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.3.4 Bayer : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.3.5 Fujirebio \(Miraca\)：近況
7.4 Fujirebio \(Miraca\)
7.4.1 Fujirebio \(Miraca\) : プロファイル
7.4.2 Fujirebio \(Miraca\) : 主な事業
7.4.3 Fujirebio \(Miraca\) : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.4.4 Fujirebio \(Miraca\) : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.4.5 Fujirebio \(Miraca\)：近況
7.5 Philips
7.5.1 Philips : プロファイル
7.5.2 Philips : 主な事業
7.5.3 Philips : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.5.4 Philips : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.5.5 Philips：近況
7.6 Merck
7.6.1 Merck : プロファイル
7.6.2 Merck : 主な事業
7.6.3 Merck : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.6.4 Merck : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.6.5 Merck：近況
7.7 Siemens Healthineers
7.7.1 Siemens Healthineers : プロファイル
7.7.2 Siemens Healthineers : 主な事業
7.7.3 Siemens Healthineers : 間質性肺疾患（ILD）の製品、サービス、ソリューション
7.7.4 Siemens Healthineers : 間質性肺疾患（ILD）の収益（百万米ドル）（2019年～2024年）
7.7.5 Siemens Healthineers：近況
8 業界チェーン分析
8.1 間質性肺疾患（ILD）業界バリューチェーン
8.2 間質性肺疾患（ILD）市場の上流分析
8.2.1 主要原材料
8.2.2 原材料と主要サプライヤー
8.2.3 製造コスト構造
8.3 中流分析
8.4 下流分析（顧客についての分析）
8.5 営業販売モデル、販売チャネル
8.5.1 間質性肺疾患（ILD） 営業販売モデル
8.5.2 販売チャネル
8.5.3 間質性肺疾患（ILD）の流通業者
9 調査の結果・結論
10 付録
10.1 調査手法
10.1.1 調査手法 / 調査アプローチ
10.1.2 データソース
10.2 執筆者の詳細
10.3 免責事項
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The global market for Interstitial Lung Disease (ILD) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Interstitial Lung Disease (ILD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Interstitial Lung Disease (ILD) include Boehringer Ingelheim, Bellerophon Therapeutics, Inc, Bayer, Fujirebio (Miraca), Philips, Merck and Siemens Healthineers, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Interstitial Lung Disease (ILD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Interstitial Lung Disease (ILD) by region & country, by Type, and by Application.
The Interstitial Lung Disease (ILD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Interstitial Lung Disease (ILD).
Market Segmentation
By Company
Boehringer Ingelheim
Bellerophon Therapeutics, Inc
Bayer
Fujirebio (Miraca)
Philips
Merck
Siemens Healthineers
Segment by Type:
Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis
Nonspecific Interstitial Pneumonitis
Hypersensitivity Pneumonitis
Cryptogenic Organizing Pneumonia
Acute Interstitial Pneumonitis
Desquamative Interstitial Pneumonitis
Others
Segment by Application
Adults
Children
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Interstitial Lung Disease (ILD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Interstitial Lung Disease (ILD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Interstitial Lung Disease (ILD) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Interstitial Lung Disease (ILD) Product Introduction
1.2 Global Interstitial Lung Disease (ILD) Market Size Forecast
1.3 Interstitial Lung Disease (ILD) Market Trends & Drivers
1.3.1 Interstitial Lung Disease (ILD) Industry Trends
1.3.2 Interstitial Lung Disease (ILD) Market Drivers & Opportunity
1.3.3 Interstitial Lung Disease (ILD) Market Challenges
1.3.4 Interstitial Lung Disease (ILD) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Interstitial Lung Disease (ILD) Players Revenue Ranking (2023)
2.2 Global Interstitial Lung Disease (ILD) Revenue by Company (2019-2024)
2.3 Key Companies Interstitial Lung Disease (ILD) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Interstitial Lung Disease (ILD) Product Offered
2.5 Key Companies Time to Begin Mass Production of Interstitial Lung Disease (ILD)
2.6 Interstitial Lung Disease (ILD) Market Competitive Analysis
2.6.1 Interstitial Lung Disease (ILD) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Interstitial Lung Disease (ILD) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Interstitial Lung Disease (ILD) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Interstitial Pneumonia
3.1.2 Idiopathic Pulmonary Fibrosis
3.1.3 Nonspecific Interstitial Pneumonitis
3.1.4 Hypersensitivity Pneumonitis
3.1.5 Cryptogenic Organizing Pneumonia
3.1.6 Acute Interstitial Pneumonitis
3.1.7 Desquamative Interstitial Pneumonitis
3.1.8 Others
3.2 Global Interstitial Lung Disease (ILD) Sales Value by Type
3.2.1 Global Interstitial Lung Disease (ILD) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Interstitial Lung Disease (ILD) Sales Value, by Type (2019-2030)
3.2.3 Global Interstitial Lung Disease (ILD) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Adults
4.1.2 Children
4.2 Global Interstitial Lung Disease (ILD) Sales Value by Application
4.2.1 Global Interstitial Lung Disease (ILD) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Interstitial Lung Disease (ILD) Sales Value, by Application (2019-2030)
4.2.3 Global Interstitial Lung Disease (ILD) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Interstitial Lung Disease (ILD) Sales Value by Region
5.1.1 Global Interstitial Lung Disease (ILD) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Interstitial Lung Disease (ILD) Sales Value by Region (2019-2024)
5.1.3 Global Interstitial Lung Disease (ILD) Sales Value by Region (2025-2030)
5.1.4 Global Interstitial Lung Disease (ILD) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.2.2 North America Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.3.2 Europe Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.4.2 Asia Pacific Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.5.2 South America Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Interstitial Lung Disease (ILD) Sales Value, 2019-2030
5.6.2 Middle East & Africa Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value
6.3 United States
6.3.1 United States Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.3.2 United States Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.4.2 Europe Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.5.2 China Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.6.2 Japan Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.7.2 South Korea Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.8.2 Southeast Asia Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Interstitial Lung Disease (ILD) Sales Value, 2019-2030
6.9.2 India Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Interstitial Lung Disease (ILD) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim Profile
7.1.2 Boehringer Ingelheim Main Business
7.1.3 Boehringer Ingelheim Interstitial Lung Disease (ILD) Products, Services and Solutions
7.1.4 Boehringer Ingelheim Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.1.5 Boehringer Ingelheim Recent Developments
7.2 Bellerophon Therapeutics, Inc
7.2.1 Bellerophon Therapeutics, Inc Profile
7.2.2 Bellerophon Therapeutics, Inc Main Business
7.2.3 Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Products, Services and Solutions
7.2.4 Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.2.5 Bellerophon Therapeutics, Inc Recent Developments
7.3 Bayer
7.3.1 Bayer Profile
7.3.2 Bayer Main Business
7.3.3 Bayer Interstitial Lung Disease (ILD) Products, Services and Solutions
7.3.4 Bayer Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.3.5 Fujirebio (Miraca) Recent Developments
7.4 Fujirebio (Miraca)
7.4.1 Fujirebio (Miraca) Profile
7.4.2 Fujirebio (Miraca) Main Business
7.4.3 Fujirebio (Miraca) Interstitial Lung Disease (ILD) Products, Services and Solutions
7.4.4 Fujirebio (Miraca) Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.4.5 Fujirebio (Miraca) Recent Developments
7.5 Philips
7.5.1 Philips Profile
7.5.2 Philips Main Business
7.5.3 Philips Interstitial Lung Disease (ILD) Products, Services and Solutions
7.5.4 Philips Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.5.5 Philips Recent Developments
7.6 Merck
7.6.1 Merck Profile
7.6.2 Merck Main Business
7.6.3 Merck Interstitial Lung Disease (ILD) Products, Services and Solutions
7.6.4 Merck Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.6.5 Merck Recent Developments
7.7 Siemens Healthineers
7.7.1 Siemens Healthineers Profile
7.7.2 Siemens Healthineers Main Business
7.7.3 Siemens Healthineers Interstitial Lung Disease (ILD) Products, Services and Solutions
7.7.4 Siemens Healthineers Interstitial Lung Disease (ILD) Revenue (US$ Million) & (2019-2024)
7.7.5 Siemens Healthineers Recent Developments
8 Industry Chain Analysis
8.1 Interstitial Lung Disease (ILD) Industrial Chain
8.2 Interstitial Lung Disease (ILD) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Interstitial Lung Disease (ILD) Sales Model
8.5.2 Sales Channel
8.5.3 Interstitial Lung Disease (ILD) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables Table 1. Interstitial Lung Disease (ILD) Market Trends Table 2. Interstitial Lung Disease (ILD) Market Drivers & Opportunity Table 3. Interstitial Lung Disease (ILD) Market Challenges Table 4. Interstitial Lung Disease (ILD) Market Restraints Table 5. Global Interstitial Lung Disease (ILD) Revenue by Company (2019-2024) & (US$ Million) Table 6. Global Interstitial Lung Disease (ILD) Revenue Market Share by Company (2019-2024) Table 7. Key Companies Interstitial Lung Disease (ILD) Manufacturing Base Distribution and Headquarters Table 8. Key Companies Interstitial Lung Disease (ILD) Product Type Table 9. Key Companies Time to Begin Mass Production of Interstitial Lung Disease (ILD) Table 10. Global Interstitial Lung Disease (ILD) Companies Market Concentration Ratio (CR5 and HHI) Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Interstitial Lung Disease (ILD) as of 2023) Table 12. Mergers & Acquisitions, Expansion Plans Table 13. Global Interstitial Lung Disease (ILD) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million) Table 14. Global Interstitial Lung Disease (ILD) Sales Value by Type (2019-2024) & (US$ Million) Table 15. Global Interstitial Lung Disease (ILD) Sales Value by Type (2025-2030) & (US$ Million) Table 16. Global Interstitial Lung Disease (ILD) Sales Market Share in Value by Type (2019-2024) & (%) Table 17. Global Interstitial Lung Disease (ILD) Sales Market Share in Value by Type (2025-2030) & (%) Table 18. Global Interstitial Lung Disease (ILD) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million) Table 19. Global Interstitial Lung Disease (ILD) Sales Value by Application (2019-2024) & (US$ Million) Table 20. Global Interstitial Lung Disease (ILD) Sales Value by Application (2025-2030) & (US$ Million) Table 21. Global Interstitial Lung Disease (ILD) Sales Market Share in Value by Application (2019-2024) & (%) Table 22. Global Interstitial Lung Disease (ILD) Sales Market Share in Value by Application (2025-2030) & (%) Table 23. Global Interstitial Lung Disease (ILD) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million) Table 24. Global Interstitial Lung Disease (ILD) Sales Value by Region (2019-2024) & (US$ Million) Table 25. Global Interstitial Lung Disease (ILD) Sales Value by Region (2025-2030) & (US$ Million) Table 26. Global Interstitial Lung Disease (ILD) Sales Value by Region (2019-2024) & (%) Table 27. Global Interstitial Lung Disease (ILD) Sales Value by Region (2025-2030) & (%) Table 28. Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030 Table 29. Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value, (2019-2024) & (US$ Million) Table 30. Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value, (2025-2030) & (US$ Million) Table 31. Boehringer Ingelheim Basic Information List Table 32. Boehringer Ingelheim Description and Business Overview Table 33. Boehringer Ingelheim Interstitial Lung Disease (ILD) Products, Services and Solutions Table 34. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Boehringer Ingelheim (2019-2024) Table 35. Boehringer Ingelheim Recent Developments Table 36. Bellerophon Therapeutics, Inc Basic Information List Table 37. Bellerophon Therapeutics, Inc Description and Business Overview Table 38. Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Products, Services and Solutions Table 39. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Bellerophon Therapeutics, Inc (2019-2024) Table 40. Bellerophon Therapeutics, Inc Recent Developments Table 41. Bayer Basic Information List Table 42. Bayer Description and Business Overview Table 43. Bayer Interstitial Lung Disease (ILD) Products, Services and Solutions Table 44. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Bayer (2019-2024) Table 45. Bayer Recent Developments Table 46. Fujirebio (Miraca) Basic Information List Table 47. Fujirebio (Miraca) Description and Business Overview Table 48. Fujirebio (Miraca) Interstitial Lung Disease (ILD) Products, Services and Solutions Table 49. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Fujirebio (Miraca) (2019-2024) Table 50. Fujirebio (Miraca) Recent Developments Table 51. Philips Basic Information List Table 52. Philips Description and Business Overview Table 53. Philips Interstitial Lung Disease (ILD) Products, Services and Solutions Table 54. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Philips (2019-2024) Table 55. Philips Recent Developments Table 56. Merck Basic Information List Table 57. Merck Description and Business Overview Table 58. Merck Interstitial Lung Disease (ILD) Products, Services and Solutions Table 59. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Merck (2019-2024) Table 60. Merck Recent Developments Table 61. Siemens Healthineers Basic Information List Table 62. Siemens Healthineers Description and Business Overview Table 63. Siemens Healthineers Interstitial Lung Disease (ILD) Products, Services and Solutions Table 64. Revenue (US$ Million) in Interstitial Lung Disease (ILD) Business of Siemens Healthineers (2019-2024) Table 65. Siemens Healthineers Recent Developments Table 66. Key Raw Materials Lists Table 67. Raw Materials Key Suppliers Lists Table 68. Interstitial Lung Disease (ILD) Downstream Customers Table 69. Interstitial Lung Disease (ILD) Distributors List Table 70. Research Programs/Design for This Report Table 71. Key Data Information from Secondary Sources Table 72. Key Data Information from Primary Sources Table 73. Business Unit and Senior & Team Lead Analysts List of Figures Figure 1. Interstitial Lung Disease (ILD) Product Picture Figure 2. Global Interstitial Lung Disease (ILD) Sales Value, 2019 VS 2023 VS 2030 (US$ Million) Figure 3. Global Interstitial Lung Disease (ILD) Sales Value (2019-2030) & (US$ Million) Figure 4. Interstitial Lung Disease (ILD) Report Years Considered Figure 5. Global Interstitial Lung Disease (ILD) Players Revenue Ranking (2023) & (US$ Million) Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Interstitial Lung Disease (ILD) Revenue in 2023 Figure 7. Interstitial Lung Disease (ILD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 Figure 8. Interstitial Pneumonia Picture Figure 9. Idiopathic Pulmonary Fibrosis Picture Figure 10. Nonspecific Interstitial Pneumonitis Picture Figure 11. Hypersensitivity Pneumonitis Picture Figure 12. Cryptogenic Organizing Pneumonia Picture Figure 13. Acute Interstitial Pneumonitis Picture Figure 14. Desquamative Interstitial Pneumonitis Picture Figure 15. Others Picture Figure 16. Global Interstitial Lung Disease (ILD) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million) Figure 17. Global Interstitial Lung Disease (ILD) Sales Value Market Share by Type, 2023 & 2030 Figure 18. Product Picture of Adults Figure 19. Product Picture of Children Figure 20. Global Interstitial Lung Disease (ILD) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million) Figure 21. Global Interstitial Lung Disease (ILD) Sales Value Market Share by Application, 2023 & 2030 Figure 22. North America Interstitial Lung Disease (ILD) Sales Value (2019-2030) & (US$ Million) Figure 23. North America Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030 Figure 24. Europe Interstitial Lung Disease (ILD) Sales Value (2019-2030) & (US$ Million) Figure 25. Europe Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030 Figure 26. Asia Pacific Interstitial Lung Disease (ILD) Sales Value (2019-2030) & (US$ Million) Figure 27. Asia Pacific Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030 Figure 28. South America Interstitial Lung Disease (ILD) Sales Value (2019-2030) & (US$ Million) Figure 29. South America Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030 Figure 30. Middle East & Africa Interstitial Lung Disease (ILD) Sales Value (2019-2030) & (US$ Million) Figure 31. Middle East & Africa Interstitial Lung Disease (ILD) Sales Value by Country (%), 2023 VS 2030 Figure 32. Key Countries/Regions Interstitial Lung Disease (ILD) Sales Value (%), (2019-2030) Figure 33. United States Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 34. United States Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 35. United States Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 36. Europe Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 37. Europe Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 38. Europe Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 39. China Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 40. China Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 41. China Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 42. Japan Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 43. Japan Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 44. Japan Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 45. South Korea Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 46. South Korea Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 47. South Korea Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 48. Southeast Asia Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 49. Southeast Asia Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 50. Southeast Asia Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 51. India Interstitial Lung Disease (ILD) Sales Value, (2019-2030) & (US$ Million) Figure 52. India Interstitial Lung Disease (ILD) Sales Value by Type (%), 2023 VS 2030 Figure 53. India Interstitial Lung Disease (ILD) Sales Value by Application (%), 2023 VS 2030 Figure 54. Interstitial Lung Disease (ILD) Industrial Chain Figure 55. Interstitial Lung Disease (ILD) Manufacturing Cost Structure Figure 56. Channels of Distribution (Direct Sales, and Distribution) Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation
